New final 340B drug discount rule from CMS could save Medicare beneficiaries an estimated $320 million in copayments in 2018 alone
GAO Releases Another Troubling Report on 340B Drug Discount Program
Report demonstrates that the 340B drug discount program is out of control and in dire need of restructuring.
CAGW Signs Coalition Letter Supporting Safety Net 340B Drug Program Reforms
The Safety Net 340B drug program must clearly define eligible patients to help them and not fatten hospital coffers.
President Trump’s Blueprint to Lower Drug Costs: A Lot to Unpack
On Friday, May 11, President Trump released his report on what his administration will do to lower drug costs.
President Trump’s Drug Costs Proposals Coming Soon
The President has already made some good policy decisions and has offered other proposals that will help to lower drug costs.
Drug Prices – The Council of Economic Advisers and Trump Administration Weigh In
Report spotlights how imposing price controls and government regulations hamper drug approvals and slow competition.
Taxpayers and Patients Win First Round on 340B Drug Discount Rule
On January 1, 2018, hospitals will begin to receive lower government reimbursements for drugs purchased under the 340B program.
New CMS Rule Will Help Reduce Drug Costs
On Wednesday, November 1, 2017, the Centers for Medicare and Medicaid Services (CMS) issued a new rule that will lower costs to taxpayers and Medicare beneficiaries for certain outpatient pharmaceuticals purchased under the 340B drug discount program. According to CMS Administrator Seema Verma, “As part of the President’s priority to lower the cost of prescription […]
How the 340B Drug Discount Program is Increasing Cancer Costs
Cancer care costs are rising, and the 340B outpatient drug discount program is needlessly contributing to the increase.
Judge Tells Federal Agency to Obey the Law for Drug Discount Program
Taxpayers and consumers pay for misuse of the 340B program through higher insurance premiums, increased drug prices and taxes.